CBPartners has evaluated several recent launches across specialty and oncology therapeutic areas to understand how G-BA / IQWiG, NICE, and the HAS view the use of surrogate endpoints in making a value-based argument, in order to better understand and mitigate the barriers likely to be encountered by manufacturers throughout the pricing and reimbursement process. Please contact Rachel Beckerman at CBPartners for a copy. (Source: Linkedin, Jan, 2014).